CINECA IRIS Institutional Research Information System

PENNA, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.724
EU - Europa 2.509
AS - Asia 2.032
OC - Oceania 150
SA - Sud America 144
AF - Africa 38
Continente sconosciuto - Info sul continente non disponibili 9
Totale 9.606
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.602
CN - Cina 999
IT - Italia 695
IE - Irlanda 356
JP - Giappone 278
DE - Germania 212
FR - Francia 210
SE - Svezia 175
KR - Corea 170
SG - Singapore 166
FI - Finlandia 145
GB - Regno Unito 144
AU - Australia 142
VN - Vietnam 136
BR - Brasile 113
CA - Canada 106
TW - Taiwan 101
PL - Polonia 94
UA - Ucraina 92
ES - Italia 91
BE - Belgio 52
HK - Hong Kong 50
IN - India 50
NL - Olanda 48
DK - Danimarca 33
CH - Svizzera 29
PT - Portogallo 25
GR - Grecia 23
NO - Norvegia 23
TR - Turchia 22
RU - Federazione Russa 16
MX - Messico 15
AT - Austria 12
CO - Colombia 12
ET - Etiopia 12
ID - Indonesia 12
HU - Ungheria 10
TH - Thailandia 10
EU - Europa 8
NZ - Nuova Zelanda 8
AR - Argentina 7
CL - Cile 7
IL - Israele 7
IR - Iran 7
NG - Nigeria 6
CZ - Repubblica Ceca 5
MY - Malesia 5
RO - Romania 5
ZA - Sudafrica 5
BD - Bangladesh 4
DZ - Algeria 4
RS - Serbia 3
SA - Arabia Saudita 3
SI - Slovenia 3
VE - Venezuela 3
BG - Bulgaria 2
EE - Estonia 2
KE - Kenya 2
MA - Marocco 2
MO - Macao, regione amministrativa speciale della Cina 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
SN - Senegal 2
ZM - Zambia 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
GH - Ghana 1
IM - Isola di Man 1
IQ - Iraq 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
NE - Niger 1
PK - Pakistan 1
PS - Palestinian Territory 1
Totale 9.606
Salva come PNG Salva come JPEG
Città #
Fairfield 453
Houston 360
Chandler 355
Dublin 341
Beijing 308
Ashburn 225
Seattle 200
Woodbridge 196
Cambridge 184
Torino 181
Wilmington 181
Ann Arbor 166
Redwood City 141
Pisa 124
Shanghai 115
Singapore 101
Villeurbanne 95
Medford 90
Princeton 90
Warsaw 78
Nyköping 76
Jacksonville 72
Dong Ket 66
Turin 63
Taipei 59
Tokyo 56
Guangzhou 47
Nanjing 47
San Diego 45
Boston 35
Sydney 34
Dearborn 33
Seoul 32
Chengdu 31
Milan 29
São Paulo 29
Melbourne 28
Barcelona 26
Phoenix 26
Wuhan 25
Columbia 24
Jinan 24
Rome 24
Munich 23
Toronto 23
Brisbane 22
Hefei 20
Helsinki 20
Norwalk 20
New York 18
Columbus 17
Hangzhou 17
Madrid 17
Silver Spring 17
Chicago 16
Duncan 16
Los Angeles 16
Brussels 15
Chongqing 15
Evanston 15
Hong Kong 15
Indianapolis 15
Shenyang 15
Boardman 14
Copenhagen 14
Dallas 14
Hanoi 14
London 14
Berlin 13
Gainesville 13
Xian 13
Montréal 12
Nanchang 12
Oslo 12
Padova 12
Zhengzhou 12
Central 11
Changsha 11
Florence 11
Hebei 11
Ottawa 11
Rochester 11
Fremont 10
Memphis 10
Pune 10
Amsterdam 9
Athens 9
Bogotá 9
Kyoto 9
Saint Paul 9
Verona 9
Xiamen 9
Central District 8
Durham 8
Kunming 8
Lund 8
Mumbai 8
Santa Clara 8
Washington 8
Aurora 7
Totale 5.658
Salva come PNG Salva come JPEG
Nome #
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 555
Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario 460
Coming back: autophagy in cachexia 431
ß-hydroxy-ß-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia 428
Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function 415
Autophagic degradation contributes to muscle wasting in cancer cachexia 400
Novel investigational drugs mimicking exercise for the treatment of cachexia 396
Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency? 306
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) 248
Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression 236
Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by Tumor Necrosis Factor-alpha 214
Mechanism-based therapeutic approaches to cachexia 203
Changes in myostatin signaling in non weight-losing cancer patients 198
Molecular and cellular mechanisms of skeletal muscle atrophy: an update 195
Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations 195
Effect of the specific proteasome inhibitor Bortezomib on cancer-related muscle wasting 192
Combined approach to counteract experimental cancer cachexia: eicosapentenoic acid and training exercise 176
Autophagy is induced in the skeletal muscle of cachectic cancer patients 173
Role of Inflammation in Muscle Homeostasis and Myogenesis 169
Vitamin D and VDR in cancer cachexia and muscle regeneration 167
New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia 154
Early changes of muscle IGF-1 and myostatin gene expression in gastric cancer patients 143
Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition 130
Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models 128
Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling 128
A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy 128
Interference with Ca 2+ -dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia 122
CASPASE 2 ACTIVATION AND ER STRESS DRIVE RAPID JURKAT CELL APOPTOSIS BY CLOFIBRATE 121
Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis 115
The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice 114
Ca(2+)-dependent proteolysis in muscle wasting. 107
Modulating metabolism to improve cancer-induced muscle wasting 103
The Skeletal Muscle as an Active Player Against Cancer Cachexia 103
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma 101
Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. 96
Animal models for cancer cachexia 90
Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses 89
A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan 88
Interleukin-4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma-bearing mice 88
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 87
Patogenesi dell'ipotrofia muscolare nella cachessia neoplastica: ruolo della via di segnalazione attivata da IGF-1 85
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy 74
Ca2+-dependent apoptosis in Jurkat cells treated with clofibrate 71
Anticytokine strategies for the treatment of cancer-related anorexia and cachexia 70
Are there any benefits for exercise training in cancer cachexia? 69
Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist 67
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? 65
Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice 63
Are antioxidants useful to treat skeletal muscle atrophy? 62
Targeting mitochondria by ss-31 ameliorates the whole body energy status in cancer-and chemotherapy-induced cachexia 61
L'inibizione del sistema proteolitico ATP-ubiquitina dipendente non previene la perdita di massa muscolare in un modello sperimentale di cachessia neoplastica 56
Extracellular vesicles derived from tumour cells as a trigger of energy crisis in the skeletal muscle 53
Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia—the effects of blocking myostatin and activins 52
MODULATIONS OF MYOSTATIN IN CANCER CACHEXIA. 49
PERTURBATIONS OF THE IGF-1 SYSTEM IN CANCER CACHEXIA 48
Protein kinases in the pathogenesis of muscle wasting 48
Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations 48
Combined Exercise Training Positively Affects Muscle Wasting in Tumor-bearing Mice 48
Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia 48
Myostatin blockade by deacetylase inhibitors fails to counteract muscle wasting in tumor-bearing mice 46
Effect of dehydroepiandrosterone in the prevention of cancer- and diabetes-induced cachexia 45
Nutritional support in cancer 43
Muscle wasting in diabetic and in tumor-bearing rats: Role of oxidative stress 42
MYOSTATIN PATHWAY: FROM EXPERIMENTAL CANCER CACHEXIA TO CANCER PATIENTS 40
MYOSTATIN EXPRESSION IS UPREGULATED IN CANCER CACHEXIA. 39
Pharmacological inhibition of the ubiquitin/proteasome ATP-dependent system does not prevent muscle wasting in experimental cancer cachexia 39
Modulations of the calcineurin/NF-AT pathway in diabetes-induced skeletal muscle atrophy. 37
The redox balance: a target for interventions against muscle wasting in cancer cachexia? 37
The role of Vitamin D in cancer cachexia 36
IGF-1 is down-regulated in experimental cancer cachexia 33
Control of skeletal muscle atrophy associated to cancer or corticosteroids by ceramide kinase 32
Research update for articles published in EJCI in 2008 31
Mechanisms of clofibrate-induced apoptosis in Yoshida AH-130 hepatoma cells 30
Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia 29
Mitochondrial dysfunction in cancer cachexia: Impact on muscle health and regeneration 27
Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia 26
Glutamine and myostatin expression in muscle 24
Sarcopenia diagnosis: Reliability of the ultrasound assessment of the tibialis anterior muscle as an alternative evaluation tool 22
Muscle myostatin signaling is enhanced in experimental cancer cachexia 21
Targeting the activin receptor signaling to counteract the multi-systemic complications of cancer and its treatments 20
Involvement of released sphingosine 1-phosphate/sphingosine 1-phosphate receptor axis in skeletal muscle atrophy 17
Exercise and Exercise Mimetics for the Treatment of Musculoskeletal Disorders 13
NAD+ repletion with niacin counteracts cancer cachexia 12
PGC-1α in the myofibers regulates the balance between myogenic and adipogenic progenitors affecting muscle regeneration 12
Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting 12
Amino Acids in Cancer and Cachexia: An Integrated View 11
Fecal miRNA profiles and gut metagenome composition in Lynch syndrome: results from a mouse model study and human subjects 5
Small non-coding RNA profiling in patients with gastrointestinal cancer 4
The BET inhibitor JQ1 targets fat metabolism and counteracts obesity 3
Extracellular Vesicles and Exosomes in the Control of the Musculoskeletal Health 2
Totale 9.919
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.298
article - articoli 0
book - libri 0
conference - conferenze 1.997
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.295
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.653 89 98 110 243 143 214 172 131 162 120 95 76
2020/20211.238 75 102 114 73 118 64 93 74 89 145 78 213
2021/20221.226 59 64 73 110 90 101 71 80 64 101 194 219
2022/20231.568 170 134 88 120 145 311 132 97 165 46 81 79
2023/20241.241 133 136 96 111 116 97 93 87 37 103 100 132
2024/202550 50 0 0 0 0 0 0 0 0 0 0 0
Totale 9.919